AstraZeneca 3Q09
3Q Revenues: $8.2 billion (+5%)
3Q Earnings: $2.1 billion (+27%)
YTD Revenues: $23.9 billion (+2%)
YTD Earnings: $6.0 billion (+27%)
Comments: Sales of Influenza A (H1N1) vaccine totaled $152 million in the quarter. Nexium sales were down 5% to $1.2 billion. Crestor sales were $1.1 billion (+24%). Seloken /Toprol-XL sales were $414 million (+103%). Symbicort sales were $562 million (+12%). Seroquel sales were $1.2 billion (+9%). Casodex sales in the U.S. were down 80% to $14 million following FDA approval of eight generic products. U.S. revenue was up 14%. Revenue in the Rest of World was up 7%. Revenue in Established Markets was up 4% and Emerging Markets was up 15%. In the quarter, diabetes treatment Onglyza was approved in the U.S. and EU.
Magazine
